HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTGâs proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG EdgeSeq chemistry and automation with next-generation sequencing (NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services. Source
No articles found.
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers...
Gilead Sciences, Inc. is a research-based bioph...
DarioHealth Corp. (NASDAQ: DRIO) is a leading global Digital Therapeutics (DTx) co...
DarioHealth Corp. (NASDAQ: DRIO) is a leading g...
InSitu Biologics is an emerging biotech company focusing on development of AnestaG...
InSitu Biologics is an emerging biotech company...
Grifols is a global healthcare company founded in Barcelona in 1909 committed to i...
Grifols is a global healthcare company founded ...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietar...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, ...
Join the National Investor Network and get the latest information with your interests in mind.